At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 83 enrolled
Drug / intervention
BMS-986158 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination With Nivolumab in Subjects With Selected Advanced Solid Tumors or Hematologic Malignancies
In Brief
A Phase 2 clinical trial evaluating BMS-986158 and Nivolumab for Advanced Tumors. Completed, enrolled 83 participants across 13 sites in 5 countries.
Detailed Summary
The purpose of this study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMS-986158 in subjects with select advanced cancers
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Tumors
CountriesAustralia, Canada, France, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 2015
Enrollment StartJun 2015
Primary CompletionMar 2021
TodayJul 2026
First PostedApr 17, 2015
Enrollment StartJun 19, 2015
Primary CompletionMar 17, 2021
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 11.2 years ago
Interventions
BMS-986158drug
Specified dose on specified days
Nivolumabbiological
Specified dose on specified days